NCT06017713

Brief Summary

This is a single-center study about patients with severe resistant OCD. Main assumption is that performing 10 tDCS sessions with the anode positioned at the level of the right orbitofrontal cortex, and the cathode at the level of the supplementary motor area, associated with the provocation of symptoms before each session is effective in the reduction in obsessive-compulsive symptoms. After the inclusion visit, the treatment period is provided from D1 to D12 (one session per day from Monday to Friday, for two consecutive weeks, i.e. a total of ten sessions). Each tDCS session lasts 30 minutes at an intensity of 2 mA and is preceded by symptom provocation using a standardized procedure performed by trained personnel. The patients are then assessed on D42 and D102 (i.e. 1 month and 3 months after the end of the tDCS sessions).

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
25

participants targeted

Target at below P25 for not_applicable

Timeline
14mo left

Started Oct 2023

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress69%
Oct 2023Jul 2027

First Submitted

Initial submission to the registry

August 24, 2023

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 30, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

October 17, 2023

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2027

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2027

Last Updated

June 5, 2025

Status Verified

June 1, 2025

Enrollment Period

3.5 years

First QC Date

August 24, 2023

Last Update Submit

June 3, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • YBOCS scale

    The primary endpoint corresponds to the change in the score on the YBOCS scale between the inclusion visit (Day 0) and the Day 42 visit. A score of 0 corresponds to the absence of OCD and a score of 40 to maximum severity.

    3,5 months

Study Arms (1)

tDCS + symptoms provocation

EXPERIMENTAL
Behavioral: tDCS + symptoms provocation

Interventions

The treatment consists of 10 sessions of tDCS. Each tDCS session lasts 30 minutes at an intensity of 2mA and is preceded by a provocation of symptoms.

tDCS + symptoms provocation

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient suffering from OCD evolving for at least 2 years diagnosed according to DSM-V criteria;
  • Patient with good insight, defined by a score less than or equal to 18 at the threshold of delusions on the BABS (Brown Assessment of Beliefs Scale) insight scale;
  • Absence of a current depressive episode (MADRS score \< 21) or suicidal risk (MADRS score item 10 \< 3);
  • Absence of epileptic pathology;
  • Chronic obsessive-compulsive disorder defined by a total YBOCS score \> 20, or a subscale score \> 15;
  • Drug-resistant obsessive-compulsive disorder despite treatment with:
  • at least 2 antidepressants of the IRS type at an effective dose and for a sufficient duration
  • and/or Behavioral and Cognitive therapy for at least 1 year;
  • Therapeutic stability (antidepressants) for more than 12 weeks without significant improvement. This treatment, at a fixed dose, will be maintained during the study;
  • Patient aged between 18 and 70 included
  • Patient who has given his/her informed consent after having received written information on the planned procedure;
  • Patient benefiting from social security or by benefiting through a third party.

You may not qualify if:

  • Woman of childbearing age without effective means of contraception (hormonal/mechanical: oral, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy)
  • Pregnant or nursing woman;
  • Patient hospitalized under duress (SPDT, SPDRE);
  • Patient under guardianship or curatorship;
  • Patient with another DSM-V Axis 1 diagnosis (Schizophrenic Disorder, Bipolar Disorder, Substance Abuse or Substance Dependence).
  • Patient suffering from a current depressive episode;
  • Patient at risk of suicide;
  • Patient with skin lesions on the scalp;
  • History of head trauma;
  • Patient with an intracerebral metal object
  • Patient with a pacemaker;
  • Presence of epileptic pathology;
  • Patient in an emergency situation or unable to give personal consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Hospitalier Henri Laborit

Poitiers, France

RECRUITING

MeSH Terms

Conditions

Obsessive-Compulsive Disorder

Interventions

Transcranial Direct Current Stimulation

Condition Hierarchy (Ancestors)

Anxiety DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeuticsConvulsive TherapyPsychiatric Somatic TherapiesBehavioral Disciplines and ActivitiesElectroshockPsychological Techniques

Central Study Contacts

Ghina HARIKA-GERMANEAU, Dr

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 24, 2023

First Posted

August 30, 2023

Study Start

October 17, 2023

Primary Completion (Estimated)

April 1, 2027

Study Completion (Estimated)

July 1, 2027

Last Updated

June 5, 2025

Record last verified: 2025-06

Locations